Skip to content

Randamized clinical trial of pars plana vitrectomy for macular edema from branch retinal vein occlusion

Randamized clinical trial of pars plana vitrectomy for macular edema from branch retinal vein occlusion - Randamized clinical trial of pars plana vitrectomy for macular edema from branch retinal vein occlusion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000433
Enrollment
160
Registered
2006-06-30
Start date
2006-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with macular edema from branch retinal vein occlusion

Interventions

Group1: grid laser photocoagulation Group2: pars plana vitrectomy

Sponsors

Kagoshima University Graduate School of Medical and Dental Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants must have center-involved macular edema secondary to branch retinal vein occlusion documented for at least 2 months and not longer 18 months Visual acuity greater than or equal to 0.1 (logMAR1.0) and less than or equal to 0.5 (logMAR0.3) Foveal retinal thickness greater than or equal to 250 microns of the optical coherence tomography (mean of 2 measurements).

Exclusion criteria

Exclusion criteria: Ischemic maculopathy and macular degeneration Presence of hemorrhage directly in the fovea Additional ocular disease reducing the visual acuity Sitting systolic blood pressure greater than 180 mmHg or diastolic blood pressure greater than 110 mmHg at the screening visit History of systemic corticosteroids within 4 months prior to randomization History of laser photocoaguration for macular edema History of major ocular surgery within 6 months prior to randomization History of peribulbar or retrobulbar or intravitreal corticosteroid use History of pars plana vitrectomy Aphakia Pregnancy History of allergy to fluorescein uncontrollable systemic disease participation in another trial

Design outcomes

Primary

MeasureTime frame
12 months distant visual acuity 12 months foveal retinal thickness

Secondary

MeasureTime frame
Course of distant visual acuity over treatment period Course of foveal retinal thickness over treatment period Ischemic maculopathy at 12 months

Countries

Japan

Contacts

Public ContactTaiji Sakamoto

Kagoshima University Graduate School of Medical and Dental Sciences Ophthalmology

tsakamot@m3.kufm.kagoshima-u.ac.jp099-275-5402

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026